Retinal disease in the C3 glomerulopathies and the risk of impaired vision

References

• Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079–1089.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Fremeaux-Bacchi V, Noel LH, et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol 2010;6:494–499
   PubMed Web of Science ®Google Scholar
• Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 2005;16:1392–1403.
   PubMed Web of Science ®Google Scholar
• Simon P, Ramee MP, Autuly V, et al. Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int 1994;46:1192–1198
   Google Scholar
• Habib R, Gubler MC, Loirat C, et al. Dense deposit disease: A variant of membranoproliferative glomerulonephritis. Kidney Int 1975;7:204–215.
   PubMed Web of Science ®Google Scholar
• Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983;74:175–192.
   Google Scholar
• Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med 1972;41(163):343–354.
   PubMedGoogle Scholar
• Mathieson PW, Peters DK. Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system. Nephrol Dial Transplant 1997;12:1804–1806.
   PubMed Web of Science ®Google Scholar
• Boon CJ, van de Kar NC, Klevering BJ, et al. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol 2009;46:1573–1594.
   PubMed Web of Science ®Google Scholar
• Boyer O, Noel LH, Balzamo E, et al. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis 2008;51:671–677.
   PubMed Web of Science ®Google Scholar
• Montes T, Goicoechea de Jorge E, Ramos R, et al. Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol 2008;45:2897–2904.
   Google Scholar
• Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009;4:22–32.
   PubMed Web of Science ®Google Scholar
• Gale DP, Pickering MC. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech 2011;4:721–726
   PubMed Web of Science ®Google Scholar
• Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010;376(9743):794–801.
   PubMed Web of Science ®Google Scholar
• Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012;7:748–756.
   PubMed Web of Science ®Google Scholar
• Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011;43:1232–1236.
   PubMed Web of Science ®Google Scholar
• Li M, Atmaca-Sonmez P, Othman M, et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet 2006;38:1049–1054.
   PubMed Web of Science ®Google Scholar
• Boon CJ, Klevering BJ, Hoyng CB, et al. Basal laminar drusen caused by compound heterozygous variants in the CFH gene. Am J Hum Genet 2008;82:516–523.
   PubMed Web of Science ®Google Scholar
• Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006;38:458–462.
   PubMed Web of Science ®Google Scholar
• Zhan X, Larson DE, Wang C, et al. Identification of a rare coding variant in Complement 3 associated with age-related macular degeneration. Nat Genet 2013;45:1375–1379.
   PubMed Web of Science ®Google Scholar
• D’Souza Y B, Jones CJ, Short CD, et al. Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II. Kidney Int 2009;75:824–827.
   PubMed Web of Science ®Google Scholar
• Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye (Lond) 2001;15(Pt 3):390–395.
   PubMed Web of Science ®Google Scholar
• Delori FC, Staurenghi G, Arend O, et al. In vivo measurement of lipofuscin in Stargardt’s disease – fundus flavimaculatus. Invest Ophthalmol Vis Sci 1995;36:2327–2331.
   PubMed Web of Science ®Google Scholar
• D’Souza Y, Jones CJ, Bonshek R. Glycoproteins of drusen and drusen-like lesions. J Mol Histol 2008;39:77–86.
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058–1066.
   PubMed Web of Science ®Google Scholar
• Ripoche J, Day AJ, Harris TJ, et al. The complete amino acid sequence of human complement factor H. Biochem J 1988;249:593–602.
   PubMed Web of Science ®Google Scholar
• Kristensen T, Wetsel RA, Tack BF. Structural analysis of human complement protein H: homology with C4b binding protein, beta 2-glycoprotein I, and the Ba fragment of B2. J Immunol 1986;136:3407–3411.
   PubMed Web of Science ®Google Scholar
• Schmidt BZ, Fowler NL, Hidvegi T, et al. Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency. J Biol Chem 1999;274:11782–11788.
   PubMed Web of Science ®Google Scholar
• Ault BH, Schmidt BZ, Fowler NL, et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997;272:25168–25175.
   Google Scholar
• Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous Factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases. J Am Soc Nephrol 2004;15:787–795.
   PubMed Web of Science ®Google Scholar
• Abrera-Abeleda MA, Nishimura C, Smith JL, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006;43:582–589.
   PubMed Web of Science ®Google Scholar
• Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001;68:478–484.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Heinen S, Jozsi M, et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006;43:97–106.
   PubMed Web of Science ®Google Scholar
• Morris KM, Aden DP, Knowles BB, et al. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 1982;70:906–913.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Chong NV. The complement system and age-related macular degeneration. Eye (Lond) 2006;20:867–872.
   PubMed Web of Science ®Google Scholar
• Schwertz R, Rother U, Anders D, et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 2001;12:166–172.
   PubMed Web of Science ®Google Scholar
• Daha MR, van Es LA. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase. J Immunol 1979;122:801–805
   PubMed Web of Science ®Google Scholar
• Colville D, Guymer R, Sinclair RA, et al. Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II (“dense deposit disease”). Am J Kidney Dis 2003;42:E2–5.
   PubMed Web of Science ®Google Scholar
• Duvall-Young J, Short CD, Raines MF, et al. Fundus changes in mesangiocapillary glomerulonephritis type II: clinical and fluorescein angiographic findings. Br J Ophthalmol 1989;73: 900–906.
   PubMed Web of Science ®Google Scholar
• Licht C, Heinen S, Jozsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006;70:42–50.
   PubMed Web of Science ®Google Scholar
• McCaughan JA, O’Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012;12:1046–1051.
   PubMed Web of Science ®Google Scholar
• Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012;366:1161–1163.
   PubMed Web of Science ®Google Scholar
• Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012;366:1163–1165.
   PubMed Web of Science ®Google Scholar
• D’Souza Y, Short CD, McLeod D, et al. Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis. Br J Ophthalmol 2008;92:950–953.
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Hakobyan S, Heng LZ, et al. Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation. Ophthalmology 2013;120:1612–1618.
   PubMed Web of Science ®Google Scholar
• Leys A, Michielsen B, Leys M, et al. Subretinal neovascular membranes associated with chronic membranoproliferative glomerulonephritis type II. Graefes Arch Clin Exp Ophthalmol 1990;228:499–504.
   PubMed Web of Science ®Google Scholar
• Farah SE, Fazelat A, Frei G. Treatment of subretinal neovascular membrane in a patient with membranoproliferative glomerulonephritis type II. Ophthalmic Surg Lasers Imaging 2009;40:416–418.
   PubMedGoogle Scholar
• Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544–546.
   PubMed Web of Science ®Google Scholar
• Members of the Age-related Eye Disease Study 2 Research Centre. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005–2015.
   PubMed Web of Science ®Google Scholar
• Weber BH, Charbel Issa P, Pauly D, et al. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int 2014;111:133–138.
   PubMed Web of Science ®Google Scholar
• Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev 2014;1:CD009300.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Fujita S, Miyazaki K, et al. C3 glomerulonephritis associated with a missense mutation in the factor H gene. Tohoku J Exp Med 2012;227:211–215.
   PubMed Web of Science ®Google Scholar
• Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82: 454–464.
   PubMed Web of Science ®Google Scholar
• Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013;45:1366–1370.
   PubMed Web of Science ®Google Scholar
• Cipriani V, Matharu BK, Khan JC, et al. Genetic variation in complement regulators and susceptibility to age-related macular degeneration. Immunobiology 2012;217:158–161.
   PubMed Web of Science ®Google Scholar
• Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702–3712.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wiesener M, Eberhardt HU, et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 2014;124:145–155.
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Lauer N, Hartmann A, et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet 2010;19:4694–4704.
   PubMed Web of Science ®Google Scholar